Lung Cancer in 2024 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include clinical decision-making, the extent emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, PA, USA
Faculty Members
David Jablons, MD
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Helen Ross, MD
Rush University Medical Center, Chicago, IL, USA
Xiuning Le, MD, PhD
MD Anderson Cancer Center, Houston, TX, USA
Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Shirish Gadgeel, MD
Henry Ford Health, Detroit, MI, USA
Fred Hirsch, MD, PhD
The Tisch Cancer Institute, New York, NY, USA
Andrew Haas, MD, PhD
University of Pennsylvania, Philadelphia, PA, USA
Martin Edelman, MD
Fox Chase Cancer Center, Philadelphia, PA, USA
Hossein Borghaei, DO
Fox Chase Cancer Center, Philadelphia, PA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Prognostic and Predictive Biomarkers in Lung Cancer (NSCLC): Pathologic Implications, Clinical and Research Relevance
- Interventional Pulmonology and Advanced Diagnostic Approaches
- Stage I–III NSCLC: How Best to Apply Immunotherapy?
- Stage I–III Oncogene-Driven NSCLC: EGFR, ALK, and Beyond
- Optimizing Immunotherapy in Unresectable and Metastatic NSCLC
- Subsequent Therapy in Stage IV NSCLC: Have We Moved Beyond Docetaxel? Will ADCs Enable Us to Do So?
- Stage IV NSCLC: EGFR Mutations
- Other Mutations in Advanced and Metastatic NSCLC (KRAS, HER2, MET, BRAF)
- Fusion-Positive, Advanced and Metastatic NSCLC (ALK, ROS1, RET, NTRK, NRG1)
- Small Cell Lung Cancer: Limited- to Extensive-Stage Disease
- Future Paradigms in Lung Cancer
